ImmuPharma (LSE:IMM) DeferredTaxAndRevenue: £0.00 Mil (As of Dec. 2025)


What is ImmuPharma DeferredTaxAndRevenue?

ImmuPharma LSE:IMM +1.13% DeferredTaxAndRevenue is £0.00 Mil as of Dec. 2025. The stock has 3 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

ImmuPharma's current deferred tax and revenue for the quarter that ended in Dec. 2025 was £0.00 Mil.

ImmuPharma DeferredTaxAndRevenue Related Terms

ImmuPharma DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for ImmuPharma's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmuPharma DeferredTaxAndRevenue Chart

ImmuPharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ImmuPharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of £0.00 Mil mean?
ImmuPharma (LSE:IMM) has a DeferredTaxAndRevenue of £0.00 Mil as of Dec. 2025. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on ImmuPharma.
Is ImmuPharma's DeferredTaxAndRevenue too high?
ImmuPharma's current DeferredTaxAndRevenue is £0.00 Mil.
How does ImmuPharma's DeferredTaxAndRevenue compare to VRTX and REGN?
ImmuPharma's DeferredTaxAndRevenue of £0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on ImmuPharma. ImmuPharma's current DeferredTaxAndRevenue is £0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuPharma stock overvalued right now?
ImmuPharma (LSE:IMM) has a current DeferredTaxAndRevenue of £0.00 Mil. The current DeferredTaxAndRevenue is £0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For ImmuPharma (LSE:IMM), the current DeferredTaxAndRevenue is £0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ImmuPharma Business Description

Other Exchanges IMMl:UK25I:Germany
Address One Bartholomew Close, London, GBR, EC1A 7BL
ImmuPharma PLC focuses on the research, development, and commercialisation of pioneering and novel drugs in specialist therapeutic areas within the pharmaceutical industry. The company's pipeline products are P140, CDx, Kapiglucagon, BioAMB, and BioCIN.